NovoSeven forventedes at begrænse blødningen og således reducere konsekvenserne af den intracerebrale hæmorrhagi.
In their official withdrawal letter, the company stated that based on this request they decided to withdraw the current application and re-submit an application upon completion of an ongoing clinical study.